top of page
Colorful Disks

Grow Your Vision

Welcome visitors to your site with a short, engaging introduction. 

Double click to edit and add your own text.


EGFR, HER2,& FLT3 Mutants Stable Cell Lines

Receptor Tyrosine Kinases

Gene function analysis, target discovery and validation, assay development, and compound screening often need cell-based assays.  Stable cell lines that are engineered to express a gene of interest via transgene integrations into the host genome provide an efficient approach to conduct such analysis. 

At Signosis, we help researchers save time and labor in generating and validating stable cell lines so scientists can spend more effort on solving the big questions.  We offer a wide selection of validated luciferase reporter cell lines that measure transcription factor activity as a read-out for various signaling pathways.

Research Solution Availability

Principle

BaF3, a murine interleukin-3 dependent pro-B cell line has been well-known as a model system for assessing downstream signaling of kinase oncogenes, and the ability of small-molecule kinase inhibitors to block kinase activity. Even though BaF3 is suitable as a transfection or transduction host, the viral delivery system is still the main approach. Signosis has been engineered as a non-viral vector-based electroporation delivery system to establish a panel of EGFR, Flt3 and Her2 and mutants BaF3 stable cell lines. The cell lines have been primarily selected with GFP, and subsequently validated with PCR-sequencing and finally confirmed western blot. The clone with the strongest expression level has been launched for facilitating drug screening and associated researches.

Benefits

Receptor Kinase  &
Mutant Stable Cell Line

Research Applications

EGFR mutants

  • Investigating the effects of EGFR mutations on downstream signaling pathways and cellular processes, such as cell proliferation, differentiation, and survival.

  • Identifying novel therapeutic strategies for targeting EGFR mutants in cancer by testing the efficacy of various inhibitors or combination therapies.

  • Screening for small molecule compounds or antibodies that selectively target EGFR mutants over wild-type EGFR.

  • Developing in vitro and in vivo models to study the mechanisms of resistance to EGFR inhibitors and to test novel combination therapies.

  • Evaluating the potential of EGFR mutants as diagnostic and prognostic biomarkers for specific types of cancer.

HER2 (ERBB2) and mutants

  • Investigating the effects of HER2 mutations on downstream signaling pathways and cellular processes, such as cell proliferation, differentiation, and survival.

  • Identifying novel therapeutic strategies for targeting HER2 and its mutants in cancer by testing the efficacy of various inhibitors or combination therapies.

  • Screening for small molecule compounds or antibodies that selectively target HER2 mutants over wild-type HER2.

  • Developing in vitro and in vivo models to study the mechanisms of resistance to HER2 inhibitors and to test novel combination therapies.

  • Evaluating the potential of HER2 and its mutants as diagnostic and prognostic biomarkers for specific types of cancer.

FLT3 and mutants

  • Investigating the effects of FLT3 mutations on downstream signaling pathways and cellular processes, such as cell proliferation, differentiation, and survival.

  • Identifying novel therapeutic strategies for targeting FLT3 and its mutants in cancer by testing the efficacy of various inhibitors or combination therapies.

  • Screening for small molecule compounds or antibodies that selectively target FLT3 mutants over wild-type FLT3.

  • Developing in vitro and in vivo models to study the mechanisms of resistance to FLT3 inhibitors and to test novel combination therapies.

  • Evaluating the potential of FLT3 and its mutants as diagnostic and prognostic biomarkers for specific types of cancer.

Baf3 Stable Cell Lines

  • Studying the signaling pathways and cellular processes that are regulated by specific receptors or mutants expressed in the Baf3 stable cell lines.

  • Identifying and characterizing novel ligands or compounds that modulate the activity of the receptors or mutants expressed in the Baf3 stable cell lines.

  • Evaluating the efficacy and selectivity of various inhibitors or combination therapies targeting the receptors or mutants expressed in the Baf3 stable cell lines.

  • Developing in vitro and in vivo models to study the effects of specific mutations or treatments on cell proliferation, differentiation, and survival in the context of the Baf3 stable cell lines.

  • Investigating the mechanisms of resistance to various inhibitors or combination therapies in the Baf3 stable cell lines, and testing novel strategies to overcome resistance.

bottom of page